Lung Non-Small Cell Carcinoma — Research

Lung Non-Small Cell Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	84,720	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	26,886	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	4,343	`("Carcinoma, Non-Small-Cell Lung"[mh] OR "Lung Carcinoma, Non-Small-Cell"[mh] OR "Nonsmall Cell Lung Cancer"[mh]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (372)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 176–200 of 372 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.
· Oncogene · 2014 · PMID 24037524 · validated civic_curation pubmed
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
· J Clin Oncol · 2009 · PMID 19884554 · validated civic_curation pubmed
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
· JCO Precis Oncol · 2020 · PMID 35050752 · validated civic_curation pubmed
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.